MedTrace Logo

Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain

NCT04082975 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2021-06-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with acute low back pain.

Conditions

  • Acute Low Back Pain

Interventions

DRUG

NVP-1203

Oral dose for 7 days

DRUG

NVP-1203-R

Oral dose for 7 days

DRUG

NVP-1203 placebo

Oral dose for 7 days

DRUG

NVP-1203-R placebo

Oral dose for 7 days

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • Seong-Hwan Moon, MD · Severance Hospital

  • Jin Hwan Kim, MD · Inje University

  • Tae Kyun Kim, MD · Wonkwang University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2021-05-24
Completion
2021-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04082975 on ClinicalTrials.gov